McKinsey & Co., the international consulting giant, agreed to pay almost $600 million final week to settle allegations by 49 states that its work for giant opioid producers helped “turbocharge” gross sales of the medication, contributing to an habit epidemic that rocked the nation and has induced greater than 400,000 deaths.

The settlement is a black eye for the agency, which holds itself out as the preeminent international guide advising companies and governments. But as a result of most of the cash to be paid by McKinsey will go to state applications funding habit therapy facilities and restoration providers, the deal may permit a McKinsey hedge fund affiliate to generate funding features, an NBC News investigation has discovered. That’s as a result of the agency’s wholly owned hedge fund affiliate, known as MIO Partners, holds oblique stakes in habit therapy facilities and a maker of overdose therapy merchandise.

In addition, funding information present, throughout the years McKinsey was serving to opioid makers propel gross sales of the medication, MIO Partners held stakes in corporations that profited from elevated utilization.

The MIO funding information do not present sufficient element to find out how a lot it has made or stands to make from opioid-related investments. But they present that MIO, which is run on behalf of present and former McKinsey staff, invested in corporations that benefited throughout the rise of the opioid disaster and now holds stakes in corporations that would profit from remediation efforts in the aftermath.

A McKinsey spokesman mentioned it’s “false and absurd” to counsel that the agency will profit financially from the huge state settlement. “McKinsey has no visibility into or control of how settlement money will be used by the states,” he mentioned. In addition, he mentioned, the hedge fund and the agency’s consulting enterprise are “operationally separate,” and the agency’s previous stakes in opioid makers by MIO have been taken by outdoors funding managers whose selections McKinsey would not direct or management.

Consulting giant McKinsey allegedly fed the opioid disaster. Now an affiliate may profit from treating addicts.

But Marianne Jennings, a professor of authorized and moral research in enterprise at the W.P. Carey School of Business at Arizona State University, mentioned the simultaneous operation of the hedge fund and McKinsey’s huge consulting enterprise poses potential conflicts that are not simply remedied.

“On conflicts of interest, there are two ways to handle them — you disclose them and manage it or you don’t do it,” Jennings mentioned. “I don’t know how you manage that unless you can show me there is absolute isolation of this fund. No matter how you slice it, you benefit. I don’t see how you don’t have an interest in that and input in that.”

MIO Partners oversees its investments with a workers and a 14-person board, regulatory filings present. Eight present or former McKinsey executives are administrators, joined by six non-McKinsey administrators, 4 of whom joined lately.

Download the NBC News app for breaking information and politics

MIO’s administration selects an array of funding managers to deploy its $14.6 billion. They make funding selections impartial of MIO and are compensated by McKinsey, in line with an impartial research commissioned by the Financial Oversight and Management Board for Puerto Rico, a federal watchdog that screens the island’s funds. After MIO selects its funding managers, it may talk about particular person investments with them, the research mentioned.

McKinsey says the MIO construction is “not unusual.” But it’s. Most giant corporations, together with all the main consulting corporations, rent third-party corporations like Fidelity and Vanguard to supervise their staff’ retirement accounts. Those corporations usually supply staff a handful of big-name mutual funds to decide on from, letting them make their very own funding selections. The holdings of such mutual funds are clear, whereas MIO’s stakes are extra opaque.

McKinsey & Co., the international consulting giant, agreed to pay almost 0 million final week to settle allegations by 49 states that its work for giant opioid producers helped "turbocharge" gross sales of the medication, contributing to an habit epidemic that rocked the nation and has induced greater than 400,000 deaths.

Since 2010, Labor Department filings present, a retirement fund managed by MIO has amassed a $108 million stake in Deerfield Management Co., a $10 billion well being care funding agency based mostly in New York. Two high Deerfield executives beforehand labored at McKinsey.

During the years McKinsey’s hedge fund has invested with Deerfield, the agency has taken giant stakes in opioid producers, in distributors of the medication and in habit therapy services. In 2018, Deerfield’s many holdings all through the sector led an anti-opioids group to label its technique “a vertical integration of human misery.”

In 2017, for instance, Deerfield was a 6 p.c shareholder in Mallinckrodt, a significant opioid maker that filed for chapter safety final 12 months after it confronted huge authorized liabilities for the function critics accused it of enjoying in the disaster. From 2011 by 2016, Deerfield held a stake — at one level valued at $90 million — in Teva Pharmaceuticals, an opioid maker and defendant in nationwide opioid litigation that it settled with plaintiffs, denying the allegations, in 2019. Deerfield additionally took stakes in two distribution corporations ensnared in government-led opioid litigation: McKesson and Cardinal Health. Both corporations have denied wrongdoing.

Deerfield did not reply to an e-mail searching for remark about its investments in the opioid trade; the telephone quantity listed on its web site has been “deactivated.”

McKinsey & Co., the international consulting giant, agreed to pay almost 0 million final week to settle allegations by 49 states that its work for giant opioid producers helped "turbocharge" gross sales of the medication, contributing to an habit epidemic that rocked the nation and has induced greater than 400,000 deaths.

In 2017, Deerfield Management agreed to pay $4.7 million to settle expenses by the Securities and Exchange Commission that it had profited in trades whereas failing to forestall its staff from misusing materials, nonpublic info. The company alleged that Deerfield had obtained nonpublic details about coming coverage modifications at the Centers for Medicare & Medicaid Services and generated over $700,000 in income. Deerfield neither admitted nor denied the allegations.

Adamis Pharmaceuticals, an organization that develops merchandise to deal with opioid overdoses, may additionally profit from opioid settlement funds. According to an SEC submitting from final summer season, MIO owned 26 p.c of the firm’s most well-liked shares; the stake was bought by an outdoors funding supervisor.

The McKinsey spokesman reiterated that its third-party managers make their selections independently of MIO.

‘Counter the emotional messages’

Investigators in Massachusetts final 12 months launched inner emails and different paperwork detailing McKinsey’s function in serving to push the sale of opioids as a guide for Purdue Pharmaceuticals, the maker of OxyContin. McKinsey labored with Purdue for 15 years, beginning in 2004, the states mentioned. Last 12 months, Purdue pleaded responsible to 3 felonies because of conduct spanning a decade — 2007 to 2017 — whereas it was working aspect by aspect with McKinsey. Purdue agreed to pay $8.3 billion.

Investigators mentioned McKinsey designed Purdue’s advertising and marketing schemes, together with a plan to “turbocharge” OxyContin gross sales at the peak of the opioid epidemic. McKinsey additionally suggested Purdue to maximise its OxyContin income by specializing in greater, extra profitable doses and scheduling extra visits by Purdue gross sales representatives to high-volume opioid prescribers. McKinsey inspired Purdue to get opioid producers to band collectively to “defend against strict treatment” by the Food and Drug Administration and labored with the firm on methods to “counter the emotional messages from mothers with teenagers that overdosed in OxyContin,” Massachusetts filings present.

Massachusetts Attorney General Maura Healey mentioned of the settlement, “Our communities will receive substantial resources for treatment, prevention, and recovery services, and families who have seen their loved ones hurt and killed by the opioid epidemic will have the truth exposed about McKinsey’s illegal and dangerous partnership with Purdue Pharma.”

Massachusetts Attorney General Maura Healey speaks to reporters at the State House in Boston on Jan. 25, 2016.Steven Senne / AP file

McKinsey mentioned it believes its previous opioid work was “lawful.” It mentioned it agreed to the settlement “without finding or admission of wrongdoing or liability of any kind.”

Money from the settlement will create the Massachusetts Opioid Recovery and Remediation Fund “to expand access to opioid use disorder prevention, intervention, treatment, and recovery options,” in line with the state.

Recovery Centers of America, an habit therapy firm by which Deerfield Management invested $331 million in 2015 and 2016, operates habit therapy services in Massachusetts, New Jersey, Pennsylvania and different states that have been a part of the McKinsey settlement.

Kevin Sneader, McKinsey’s international managing companion, mentioned that in placing the settlement, “we chose to resolve this matter in order to provide fast, meaningful support to communities across the United States.”

“We deeply regret that we did not adequately acknowledge the tragic consequences of the epidemic unfolding in our communities,” he mentioned. “With this agreement, we hope to be part of the solution to the opioid crisis in the U.S.”

McKinsey’s hedge fund has come underneath scrutiny earlier than. In 2018, The Wall Street Journal reported that the hedge fund held funding stakes in corporations it had suggested in chapter proceedings. The proceedings require advisers to be unconflicted of their work, and guidelines bar them from having stakes in circumstances’ outcomes. In 2019, McKinsey paid $15 million to settle an inquiry by a unit of the Justice Department into whether or not it violated disclosure guidelines designed to forestall conflicts of curiosity in company bankruptcies.

And the 2019 research commissioned by Puerto Rico monetary oversight board famous that MIO investments in that chapter case “could be perceived as a conflict.”